Sunday 26 January 2020 ,
Sunday 26 January 2020 ,
Latest News
  • Common people’s uplift is prerequisite to country’s development: PM
  • Turkey earthquake: Death toll climbs to 35
  • Shakib feels blessed receiving food cooked by PM
  • AL mayoral candidate Atiqul promises ‘modern, dynamic, healthy’ Dhaka
  • Dhaka City Polls: BNP candidate Ishraque attacked
  • 3 pvt universities fined for enrolling extra students
  • Virus death toll in China rises to 56
  • PM opens water treatment plants in Khulna, Ctg
  • Coronavirus virus: Bangladeshi students appeal for help in China
9 October, 2019 12:28:00 PM
Print

Johnson & Johnson must pay $8 bn over drug side effect: jury

Independent Online/AFP
Johnson & Johnson must pay $8 bn over drug side effect: jury
Johnson & Johnson said it was "confident (the ruling) will be overturned," calling the $8bn jury award against it "grossly disproportionate"

A Pennsylvania jury ruled Tuesday that US pharmaceutical giant Johnson & Johnson must pay $8 billion in damages and interest for failing to warn that a psychiatric drug could cause breast growth in men.

Johnson & Johnson and its subsidiary Janssen Pharmaceuticals were blamed as plaintiff Nicholas Murray told the Philadelphia court that the drug Risperdal, prescribed to treat schizophrenia and bipolar disorder, had made him grow breasts.

The company challenged the ruling in a statement, calling the damages awarded "grossly disproportionate" with the initial award in the case of $680,000.

"The company is confident (the ruling) will be overturned," the statement said, and "will be immediately moving to set aside this excessive and unfounded verdict."

In the statement, Johnson & Johnson accused the court of preventing their defense team from presenting "key evidence" on Risperdal labeling.

The company is facing a series of complaints in state courts for failing to properly warn of Risperdal's side effects, including in Pennsylvania, California and Missouri.

Risperdal, approved for the treatment of adults by the US Food and Drug Administration in 1993, brought in some $737 million (672 million euros) in sales in 2018.

HM

Comments

Video
More Business Stories
Bourses begin week in upbeat Country’s premier bourse, Dhaka Stock Exchange (DSE) on Sunday began week extending the gaining note of previous session. The broad index, DSEX closed at 4528.20 points on Sunday, first working day of week, with a gain of 14.31…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting